Fulgent Genetics (FLGT)

• Market cap: $577M
• 1 day: -1.01%
• 5 days: 3.32%
• 1 month: 9.62%
• 3 months: 8.79%
• 6 months: -6.17%
• Year to date: 1.47%
• 1 year: -9.18%
• 5 years: 15.73%
• 10 years: 103.59%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Employees: 1,313

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4,613% more call options, than puts

Call options by funds: $43.5M | Put options by funds: $924K

45% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 49

24% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 25

3% more funds holding

Funds holding: 182 [Q3] → 187 (+5) [Q4]

2.51% more ownership

Funds ownership: 53.11% [Q3] → 55.62% (+2.51%) [Q4]

10% less capital invested

Capital invested by funds: $350M [Q3] → $314M (-$35.4M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $16 14% downside
• Avg. target: $16 14% downside
• High target: $16 14% downside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target

14% downside $16

Neutral Maintained

4 Mar 2025